---

$25.07

+0.9350 ( +3.88% ) 231.8K

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Open	$25.07
Previous Close	$24.13
Volume	231.8K
Market Cap	$848.59M
Day Range	$22.30 - $25.65
52 Week Range	$13.89 - $33.20
Shares Outstanding	36.02M
Change %	+3.88%
Net Change	▲ 0.9350
Insider Ownership	N/A
Exchange	NYSE
Sector
Industry	PHARMACEUTICAL PREPARATIONS
IPO Year	2025
Country	United States
Underwriter	Morgan Stanley, Leerink Partners, Evercore ISI, Cantor Fitzgerald, more

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
No records found.